Oryzon Genomics Management

Management criteria checks 2/4

Oryzon Genomics' CEO is Carlos Manuel Arjol, appointed in Jan 2000, has a tenure of 24.33 years. directly owns 5.04% of the company’s shares, worth €5.69M. The average tenure of the management team and the board of directors is 3.6 years and 8.5 years respectively.

Key information

Carlos Manuel Arjol

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	24.3yrs
CEO ownership	5.0%
Management average tenure	3.6yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO

Carlos Manuel Arjol

24.3yrs

Tenure

US$62,992

Compensation

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Carlos Manuel Arjol	Co-Founder	24.3yrs	US$62.99k	5.04% $ 5.7m
Enric Condomines	Director of Operations	3.9yrs	no data	no data
Jordi Pey	Chief Scientific Officer	3.3yrs	no data	no data
Xavier Ribera	Head of Internal Audit & Compliance	no data	no data	no data
Emili Cortada	Chief Business Development Officer	no data	no data	no data
Neus Bernado	Chief Intellectual Property Officer	12.7yrs	no data	no data
Michael Ropacki	Chief Medical Officer of CNS	3.3yrs	no data	no data
Sonia Paloma Bezon	Chief of Clinical Operations	6.6yrs	no data	no data
Ana Limon	Senior Vice President of Clinical Development & Global Medical Affairs	2.3yrs	no data	no data
Douglas Faller	Global Chief Medical Officer	2.2yrs	no data	no data
Augusto Rubio	Secretary	no data	no data	no data

3.6yrs

Average Tenure

Experienced Management: ORN's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Carlos Manuel Arjol	Co-Founder	23.3yrs	US$62.99k	5.04% $ 5.7m
Howard Fillit	Member of Scientific Advisory Board	no data	no data	no data
Isabel Navarro	Independent Director	8.5yrs	US$7.60k	no data
Lori Kunkel	Member of Scientific Advisory Board	6.3yrs	no data	no data
Manuel López-Figueroa	Lead Independent Director	4yrs	no data	no data
Josep Echarri Torres	Director	22.3yrs	US$6.52k	2.16% $ 2.4m
Tamara Maes	VP of the Board & President of Scientific Advisory Board	24.3yrs	US$62.99k	4.33% $ 4.9m
Ramon Ramon	Independent Director	8.5yrs	US$7.60k	0.032% $ 35.9k
Leon Hooftman	Member of Scientific Advisory Board	no data	no data	no data
Antonio Melero	Independent Director	8.5yrs	US$7.60k	no data
Felipe Cardoso	Member of Scientific Advisory Board	no data	no data	no data
Jose Molinuevo	Member of Scientific Advisory Board	no data	no data	no data

8.5yrs

Average Tenure

65yo

Average Age

Experienced Board: ORN's board of directors are considered experienced (8.5 years average tenure).

Oryzon Genomics Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Oryzon Genomics S.A. Announces Executive Changes

Recent updates

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast breakeven date pushed back to 2026

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

Forecast to breakeven in 2025

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.75

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.10

New 90-day low: €2.64

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.65

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age